Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Retained Earnings: 2017-2024

Historic Retained Earnings for Protagonist Therapeutics (PTGX) over the last 8 years, with Dec 2024 value amounting to -$340.5 million.

  • Protagonist Therapeutics' Retained Earnings rose 9.72% to -$426.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$426.3 million, marking a year-over-year increase of 9.72%. This contributed to the annual value of -$340.5 million for FY2024, which is 44.69% up from last year.
  • As of FY2024, Protagonist Therapeutics' Retained Earnings stood at -$340.5 million, which was up 44.69% from -$615.7 million recorded in FY2023.
  • Over the past 5 years, Protagonist Therapeutics' Retained Earnings peaked at -$283.8 million during FY2020, and registered a low of -$615.7 million during FY2023.
  • Over the past 3 years, Protagonist Therapeutics' median Retained Earnings value was -$536.8 million (recorded in 2022), while the average stood at -$497.7 million.
  • As far as peak fluctuations go, Protagonist Therapeutics' Retained Earnings crashed by 44.24% in 2021, and later surged by 44.69% in 2024.
  • Over the past 5 years, Protagonist Therapeutics' Retained Earnings (Yearly) stood at -$283.8 million in 2020, then tumbled by 44.24% to -$409.4 million in 2021, then slumped by 31.12% to -$536.8 million in 2022, then fell by 14.71% to -$615.7 million in 2023, then skyrocketed by 44.69% to -$340.5 million in 2024.